Altria Group, Inc. (MO) Earnings
Altria Group, Inc. is expected to report next earnings on July 30, 2026 (in NaN days), with a consensus EPS estimate of $1.48. MO has beaten EPS estimates in 3 of its last 12 reported quarters (average surprise +2.1% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Apr 30, 2026 | $1.25 | $1.32 | +5.6% | $4.8B | +3.9% |
| Jan 29, 2026 | $1.32 | $1.30 | -1.5% | $5.8B | +16.2% |
| Oct 30, 2025 | $1.44 | $1.45 | +0.7% | $5.3B | -0.8% |
| Jul 30, 2025 | $1.39 | $1.44 | +3.6% | $5.3B | +1.9% |
| Jan 30, 2025 | $1.28 | $1.29 | +0.8% | $5.1B | +1.2% |
| Oct 31, 2024 | $1.35 | $1.38 | +2.2% | $5.3B | +0.3% |
| Jul 31, 2024 | $1.34 | $1.31 | -2.2% | $5.3B | -2.1% |
| Apr 25, 2024 | $1.15 | $1.15 | +0.0% | $4.7B | +0.1% |
| Feb 1, 2024 | $1.17 | $1.18 | +0.9% | $5.0B | +7.7% |
| Oct 26, 2023 | $1.29 | $1.28 | -0.8% | $5.3B | +3.1% |
| Aug 1, 2023 | $1.30 | $1.31 | +0.8% | $5.4B | +0.2% |
| Apr 27, 2023 | $1.18 | $1.18 | +0.0% | $4.8B | -2.9% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · April 30, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Strong start to the year with adjusted diluted EPS up 7.3%. Highly cash generative businesses supported returns to shareholders. Smokable product segment income growth, marble in premium, PMUSA portfolio strategy. Orn and nicotine pouch performance, Helix's results and marketing efforts. eVapor category moderation due to enforcement and supply issues. Regulatory updates on ONPlus. Macroeconomic challenges affecting consumers, trade-down in cigarette segment. Investment in ABI, dividends and share repurchases.
Guidance
Reaffirmed 2026 full year adjusted diluted EPS range of $5.56 to $5.72, growth 2.5%-5.5% from 2025. Strong Q1 performance leads to more balanced growth between first half and second half. Considers moderated evapor industry growth and macroeconomic uncertainty.
Segment performance
Smokable Product Segment: Generated strong income growth. Marble strengthened position in premium segment. PMUSA executed total portfolio strategy. Reported domestic cigarette volumes declined by 2.4%, but Marlboro expanded share in premium segment. BASIC captured share in discount segment. Cigars shipment volume down slightly, but Middleton outperformed. Oral Tobacco Product Segment: Delivered over $400 million in total adjusted OCI in Q1. Adjusted OCI margins 67.4%. Total segment reported shipment volume decreased 3.1%. Helix expanded portfolio in nicotine pouch category. Oil Tobacco Product Segment: Orn performed well, Helix expanded Orn Plus nationwide. Nicotine pouch category grew 9.1 share points, now over 58% of total oral tobacco.
Risks & headwinds
Illicit flavored disposable products still prevalent, impacting eVapor category growth. Macro-economic challenges affecting consumer discretionary income, pressure on discount segment. Limited FDA authorized eVapor products constraining category progress. Regulatory uncertainties and enforcement effectiveness.